Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Jun;84(12):1616–1623. doi: 10.1054/bjoc.2001.1845

Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women

C Clavel 1, M Masure 1, J-P Bory 2, I Putaud 1, C Mangeonjean 1, M Lorenzato 1, P Nazeyrollas 3, R Gabriel 2, C Quereux 2, P Birembaut 1
PMCID: PMC2363679  PMID: 11401314

Abstract

High-risk human papillomaviruses (HR-HPV) are the necessary cause of cervical carcinomas. To determine whether HPR-HPV DNA detection in primary routine screening could represent a sensitive and reliable technique for the detection of high-grade squamous intraepithelial lesions (HGSIL), laboratory analysis using 2 cytologic techniques (conventional and liquid-based), HPV testing with Hybrid Capture II assay (HC-II), followed by colposcopic examination of women with abnormal cervical finding and/or persistent HR-HPV infection, was conducted in 7932 women who had routine cervical examination. The sensitivity of HPV testing for detecting a histologically proven HGSIL was 100%, higher than that of conventional (68.1%) and liquid-based (87.8%) cytology. The low specificities of 85.6% and 87.3% of HPV testing slightly increased to 88.4% and 90.1% if HPV testing was reserved for woman >30 years old. The quantitative approach provided by the HC-II assay for the assessment of the viral load was not reliable for predicting HGSIL in normal smears. HR-HPV testing could be proposed in primary screening in association with cytology. With conventional cytology it significantly improves the detection of HGSIL. With the use of the same cervical scrape for HPV testing and liquid-based cytology, HR-HPV testing would allow to select positive samples treated in a second time for cytology which gives a good specificity. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: HPV, cervical cancer, screening

Full Text

The Full Text of this article is available as a PDF (81.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adam E., Kaufman R. H., Berkova Z., Icenogle J., Reeves W. C. Is human papillomavirus testing an effective triage method for detection of high-grade (grade 2 or 3) cervical intraepithelial neoplasia? Am J Obstet Gynecol. 1998 Jun;178(6):1235–1244. doi: 10.1016/s0002-9378(98)70328-x. [DOI] [PubMed] [Google Scholar]
  2. Bosch F. X., Manos M. M., Muñoz N., Sherman M., Jansen A. M., Peto J., Schiffman M. H., Moreno V., Kurman R., Shah K. V. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995 Jun 7;87(11):796–802. doi: 10.1093/jnci/87.11.796. [DOI] [PubMed] [Google Scholar]
  3. Clavel C., Bory J. P., Rihet S., Masure M., Duval-Binninger I., Putaud I., Lorenzato M., Quereux C., Birembaut P. Comparative analysis of human papillomavirus detection by hybrid capture assay and routine cytologic screening to detect high-grade cervical lesions. Int J Cancer. 1998 Feb 9;75(4):525–528. doi: 10.1002/(sici)1097-0215(19980209)75:4<525::aid-ijc6>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  4. Clavel C., Masure M., Bory J. P., Putaud I., Mangeonjean C., Lorenzato M., Gabriel R., Quereux C., Birembaut P. Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br J Cancer. 1999 Jul;80(9):1306–1311. doi: 10.1038/sj.bjc.6690523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Clavel C., Masure M., Putaud I., Thomas K., Bory J. P., Gabriel R., Quereux C., Birembaut P. Hybrid capture II, a new sensitive test for human papillomavirus detection. Comparison with hybrid capture I and PCR results in cervical lesions. J Clin Pathol. 1998 Oct;51(10):737–740. doi: 10.1136/jcp.51.10.737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cox J. T., Lorincz A. T., Schiffman M. H., Sherman M. E., Cullen A., Kurman R. J. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 1995 Mar;172(3):946–954. doi: 10.1016/0002-9378(95)90026-8. [DOI] [PubMed] [Google Scholar]
  7. Cuzick J., Beverley E., Ho L., Terry G., Sapper H., Mielzynska I., Lorincz A., Chan W. K., Krausz T., Soutter P. HPV testing in primary screening of older women. Br J Cancer. 1999 Oct;81(3):554–558. doi: 10.1038/sj.bjc.6690730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cuzick J., Sasieni P., Davies P., Adams J., Normand C., Frater A., van Ballegooijen M., van den Akker-van Marle E. A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions. Br J Cancer. 2000 Sep;83(5):561–565. doi: 10.1054/bjoc.2000.1375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cuzick J., Szarewski A., Terry G., Ho L., Hanby A., Maddox P., Anderson M., Kocjan G., Steele S. T., Guillebaud J. Human papillomavirus testing in primary cervical screening. Lancet. 1995 Jun 17;345(8964):1533–1536. doi: 10.1016/s0140-6736(95)91086-7. [DOI] [PubMed] [Google Scholar]
  10. Cuzick J., Terry G., Ho L., Hollingworth T., Anderson M. Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. Br J Cancer. 1994 Jan;69(1):167–171. doi: 10.1038/bjc.1994.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Franco E. L., Villa L. L., Sobrinho J. P., Prado J. M., Rousseau M. C., Désy M., Rohan T. E. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999 Nov;180(5):1415–1423. doi: 10.1086/315086. [DOI] [PubMed] [Google Scholar]
  12. Gaarenstroom K.N., Melkert P., Walboomers J.M.M., Van Den Brule A.J.C., Van Bommel P.F.J., Meyer C.J.L.M., Voorhorst F.J., Kenemans P., Helmerhorst Th.J.M. Human papillomavirus DNA and genotypes: prognostic factors for progression of cervical intraepithelial neoplasia. Int J Gynecol Cancer. 1994 Mar;4(2):73–78. doi: 10.1046/j.1525-1438.1994.04020073.x. [DOI] [PubMed] [Google Scholar]
  13. Gustafsson L., Adami H. O. Natural history of cervical neoplasia: consistent results obtained by an identification technique. Br J Cancer. 1989 Jul;60(1):132–141. doi: 10.1038/bjc.1989.236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Herrero R., Hildesheim A., Bratti C., Sherman M. E., Hutchinson M., Morales J., Balmaceda I., Greenberg M. D., Alfaro M., Burk R. D. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst. 2000 Mar 15;92(6):464–474. doi: 10.1093/jnci/92.6.464. [DOI] [PubMed] [Google Scholar]
  15. Ho G. Y., Bierman R., Beardsley L., Chang C. J., Burk R. D. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998 Feb 12;338(7):423–428. doi: 10.1056/NEJM199802123380703. [DOI] [PubMed] [Google Scholar]
  16. Ho G. Y., Burk R. D., Klein S., Kadish A. S., Chang C. J., Palan P., Basu J., Tachezy R., Lewis R., Romney S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 1995 Sep 20;87(18):1365–1371. doi: 10.1093/jnci/87.18.1365. [DOI] [PubMed] [Google Scholar]
  17. Kaufman R. H., Adam E. Is human papillomavirus testing of value in clinical practice? Am J Obstet Gynecol. 1999 May;180(5):1049–1053. doi: 10.1016/s0002-9378(99)70593-4. [DOI] [PubMed] [Google Scholar]
  18. Koutsky L. A., Holmes K. K., Critchlow C. W., Stevens C. E., Paavonen J., Beckmann A. M., DeRouen T. A., Galloway D. A., Vernon D., Kiviat N. B. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992 Oct 29;327(18):1272–1278. doi: 10.1056/NEJM199210293271804. [DOI] [PubMed] [Google Scholar]
  19. Kuhn L., Denny L., Pollack A., Lorincz A., Richart R. M., Wright T. C. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst. 2000 May 17;92(10):818–825. doi: 10.1093/jnci/92.10.818. [DOI] [PubMed] [Google Scholar]
  20. Liaw K. L., Hildesheim A., Burk R. D., Gravitt P., Wacholder S., Manos M. M., Scott D. R., Sherman M. E., Kurman R. J., Glass A. G. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis. 2000 Nov 16;183(1):8–15. doi: 10.1086/317638. [DOI] [PubMed] [Google Scholar]
  21. Lorincz A. T., Reid R., Jenson A. B., Greenberg M. D., Lancaster W., Kurman R. J. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol. 1992 Mar;79(3):328–337. doi: 10.1097/00006250-199203000-00002. [DOI] [PubMed] [Google Scholar]
  22. Manos M. M., Kinney W. K., Hurley L. B., Sherman M. E., Shieh-Ngai J., Kurman R. J., Ransley J. E., Fetterman B. J., Hartinger J. S., McIntosh K. M. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA. 1999 May 5;281(17):1605–1610. doi: 10.1001/jama.281.17.1605. [DOI] [PubMed] [Google Scholar]
  23. Meijer C. J., Helmerhorst T. J., Rozendaal L., van der Linden J. C., Voorhorst F. J., Walboomers J. M. HPV typing and testing in gynaecological pathology: has the time come? Histopathology. 1998 Jul;33(1):83–86. doi: 10.1046/j.1365-2559.1998.00436.x. [DOI] [PubMed] [Google Scholar]
  24. Papillo J. L., Zarka M. A., St John T. L. Evaluation of the ThinPrep Pap test in clinical practice. A seven-month, 16,314-case experience in northern Vermont. Acta Cytol. 1998 Jan-Feb;42(1):203–208. doi: 10.1159/000331547. [DOI] [PubMed] [Google Scholar]
  25. Peyton C. L., Schiffman M., Lörincz A. T., Hunt W. C., Mielzynska I., Bratti C., Eaton S., Hildesheim A., Morera L. A., Rodriguez A. C. Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol. 1998 Nov;36(11):3248–3254. doi: 10.1128/jcm.36.11.3248-3254.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ratnam S., Franco E. L., Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):945–951. [PubMed] [Google Scholar]
  27. Remmink A. J., Walboomers J. M., Helmerhorst T. J., Voorhorst F. J., Rozendaal L., Risse E. K., Meijer C. J., Kenemans P. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer. 1995 May 4;61(3):306–311. doi: 10.1002/ijc.2910610305. [DOI] [PubMed] [Google Scholar]
  28. Riethmuller D., Gay C., Bertrand X., Bettinger D., Schaal J. P., Carbillet J. P., Lassabe C., Arveux P., Seilles E., Mougin C. Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction. Diagn Mol Pathol. 1999 Sep;8(3):157–164. doi: 10.1097/00019606-199909000-00009. [DOI] [PubMed] [Google Scholar]
  29. Rozendaal L., Walboomers J. M., van der Linden J. C., Voorhorst F. J., Kenemans P., Helmerhorst T. J., van Ballegooijen M., Meijer C. J. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer. 1996 Dec 11;68(6):766–769. doi: 10.1002/(SICI)1097-0215(19961211)68:6<766::AID-IJC13>3.0.CO;2-Z. [DOI] [PubMed] [Google Scholar]
  30. Schiffman M., Herrero R., Hildesheim A., Sherman M. E., Bratti M., Wacholder S., Alfaro M., Hutchinson M., Morales J., Greenberg M. D. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA. 2000 Jan 5;283(1):87–93. doi: 10.1001/jama.283.1.87. [DOI] [PubMed] [Google Scholar]
  31. Schneider A., Zahm D. M., Kirchmayr R., Schneider V. L. Screening for cervical intraepithelial neoplasia grade 2/3: validity of cytologic study, cervicography, and human papillomavirus detection. Am J Obstet Gynecol. 1996 May;174(5):1534–1541. doi: 10.1016/s0002-9378(96)70602-6. [DOI] [PubMed] [Google Scholar]
  32. Sherman M. E., Mendoza M., Lee K. R., Ashfaq R., Birdsong G. G., Corkill M. E., McIntosh K. M., Inhorn S. L., Zahniser D. J., Baber G. Performance of liquid-based, thin-layer cervical cytology: correlation with reference diagnoses and human papillomavirus testing. Mod Pathol. 1998 Sep;11(9):837–843. [PubMed] [Google Scholar]
  33. Solomon D., Schiffman M., Tarone R., ALTS Study group Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001 Feb 21;93(4):293–299. doi: 10.1093/jnci/93.4.293. [DOI] [PubMed] [Google Scholar]
  34. Stoler M. H. Advances in cervical screening technology. Mod Pathol. 2000 Mar;13(3):275–284. doi: 10.1038/modpathol.3880048. [DOI] [PubMed] [Google Scholar]
  35. Vernon S. D., Unger E. R., Williams D. Comparison of human papillomavirus detection and typing by cycle sequencing, line blotting, and hybrid capture. J Clin Microbiol. 2000 Feb;38(2):651–655. doi: 10.1128/jcm.38.2.651-655.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Walboomers J. M., Jacobs M. V., Manos M. M., Bosch F. X., Kummer J. A., Shah K. V., Snijders P. J., Peto J., Meijer C. J., Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999 Sep;189(1):12–19. doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  37. Weintraub J., Morabia A. Efficacy of a liquid-based thin layer method for cervical cancer screening in a population with a low incidence of cervical cancer. Diagn Cytopathol. 2000 Jan;22(1):52–59. doi: 10.1002/(sici)1097-0339(200001)22:1<52::aid-dc14>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  38. Wright T. C., Jr, Lorincz A., Ferris D. G., Richart R. M., Ferenczy A., Mielzynska I., Borgatta L. Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears. Am J Obstet Gynecol. 1998 May;178(5):962–966. doi: 10.1016/s0002-9378(98)70531-9. [DOI] [PubMed] [Google Scholar]
  39. Ylitalo N., Sørensen P., Josefsson A. M., Magnusson P. K., Andersen P. K., Pontén J., Adami H. O., Gyllensten U. B., Melbye M. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet. 2000 Jun 24;355(9222):2194–2198. doi: 10.1016/S0140-6736(00)02402-8. [DOI] [PubMed] [Google Scholar]
  40. zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol. 1994;186:131–156. doi: 10.1007/978-3-642-78487-3_8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES